Literature DB >> 21554913

Characterization of antigenic regions in the porcine reproductive and respiratory syndrome virus by the use of peptide-specific serum antibodies.

Merijn Vanhee1, Wander Van Breedam, Sarah Costers, Marc Geldhof, Ytse Noppe, Hans Nauwynck.   

Abstract

The porcine reproductive and respiratory syndrome virus (PRRSV) is an RNA virus that causes reproductive failure in sows and boars, and respiratory disease in pigs of all ages. Antibodies against several viral envelope proteins are produced upon infection, and the glycoproteins GP4 and GP5 are known targets for virus neutralization. Still, substantial evidence points to the presence of more, yet unidentified neutralizing antibody targets in the PRRSV envelope proteins. The current study aimed to identify and characterize linear antigenic regions (ARs) within the entire set of envelope proteins of the European prototype PRRSV strain Lelystad virus (LV). Seventeen LV-specific antisera were tested in pepscan analysis on GP2, E, GP3, GP4, GP5 and M, resulting in the identification of twenty-one ARs that are capable of inducing antibodies upon infection in pigs. A considerable number of these ARs correspond to previously described epitopes in different European- and North-American-type PRRSV strains. Remarkably, the largest number of ARs was found in GP3, and two ARs in the GP3 ectodomain consistently induced antibodies in a majority of infected pigs. In contrast, all remaining ARs, except for a highly immunogenic epitope in GP4, were only recognized by one or a few infected animals. Sensitivity to antibody-mediated neutralization was tested for a selected number of ARs by in vitro virus-neutralization tests on alveolar macrophages with peptide-purified antibodies. In addition to the known neutralizing epitope in GP4, two ARs in GP2 and one in GP3 turned out to be targets for virus-neutralizing antibodies. No virus-neutralizing antibody targets were found in E, GP5 or M. Since the neutralizing AR in GP3 induced antibodies in a majority of infected pigs, the immunogenicity of this AR was studied more extensively, and it was demonstrated that the corresponding region in GP3 of virus strains other than LV also induces virus-neutralizing antibodies. This study provides new insights into PRRSV antigenicity, and contributes to the knowledge on protective immunity and immune evasion strategies of the virus.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21554913     DOI: 10.1016/j.vaccine.2011.04.071

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  42 in total

1.  Porcine reproductive and respiratory syndrome virus neutralizing antibodies provide in vivo cross-protection to PRRSV1 and PRRSV2 viral challenge.

Authors:  Sally R Robinson; Michael C Rahe; Diem K Gray; Kyra V Martins; Michael P Murtaugh
Journal:  Virus Res       Date:  2018-02-03       Impact factor: 3.303

2.  A single amino acid deletion in the matrix protein of porcine reproductive and respiratory syndrome virus confers resistance to a polyclonal swine antibody with broadly neutralizing activity.

Authors:  Benjamin R Trible; Luca N Popescu; Nicholas Monday; Jay G Calvert; Raymond R R Rowland
Journal:  J Virol       Date:  2015-04-08       Impact factor: 5.103

3.  Identification of epitopes on nonstructural protein 7 of porcine reproductive and respiratory syndrome virus recognized by monoclonal antibodies using phage-display technology.

Authors:  Heng Wang; Rongchang Liu; Weidong Zhang; Lingshuang Sun; Zhangyong Ning; Fangxiao Ji; Jin Cui; Guihong Zhang
Journal:  Virus Genes       Date:  2017-06-08       Impact factor: 2.332

4.  Nsp2 and GP5-M of Porcine Reproductive and Respiratory Syndrome Virus Contribute to Targets for Neutralizing Antibodies.

Authors:  Jia Su; Lei Zhou; Bicheng He; Xinhui Zhang; Xinna Ge; Jun Han; Xin Guo; Hanchun Yang
Journal:  Virol Sin       Date:  2019-07-25       Impact factor: 4.327

5.  Attenuation of porcine reproductive and respiratory syndrome virus by molecular breeding of virus envelope genes from genetically divergent strains.

Authors:  Yan-Yan Ni; Tanja Opriessnig; Lei Zhou; Dianjun Cao; Yao-Wei Huang; Patrick G Halbur; Xiang-Jin Meng
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

6.  Glycoprotein 3 of Porcine Reproductive and Respiratory Syndrome Virus Exhibits an Unusual Hairpin-Like Membrane Topology.

Authors:  Minze Zhang; Ludwig Krabben; Fangkun Wang; Michael Veit
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

7.  Temporal lineage dynamics of the ORF5 gene of porcine reproductive and respiratory syndrome virus in Korea in 2014-2019.

Authors:  Seung-Chai Kim; Chang-Gi Jeong; Gyeong-Seo Park; Ji-Young Park; Hye-Young Jeoung; Go-Eun Shin; Mi-Kyeong Ko; Seoung-Hee Kim; Kyoung-Ki Lee; Won-Il Kim
Journal:  Arch Virol       Date:  2021-08-10       Impact factor: 2.574

8.  A Synthetic Porcine Reproductive and Respiratory Syndrome Virus Strain Confers Unprecedented Levels of Heterologous Protection.

Authors:  Hiep L X Vu; Fangrui Ma; William W Laegreid; Asit K Pattnaik; David Steffen; Alan R Doster; Fernando A Osorio
Journal:  J Virol       Date:  2015-09-23       Impact factor: 5.103

9.  Porcine Reproductive and Respiratory Syndrome Virus Promotes SLA-DR-Mediated Antigen Presentation of Nonstructural Proteins To Evoke a Nonneutralizing Antibody Response In Vivo.

Authors:  Chunyan Wu; Bingjun Shi; Di Yang; Kun Zhang; Jie Li; Jie Wang; Hongliang Liu; Qin Zhao; En-Min Zhou; Yuchen Nan
Journal:  J Virol       Date:  2020-10-14       Impact factor: 5.103

10.  Chimeric HP-PRRSV2 containing an ORF2-6 consensus sequence induces antibodies with broadly neutralizing activity and confers cross protection against virulent NADC30-like isolate.

Authors:  Nanhua Chen; Shubin Li; Yunfei Tian; Xinshuai Li; Shuai Li; Jixiang Li; Ming Qiu; Zhe Sun; Yanzhao Xiao; Xilin Yan; Hong Lin; Xiuling Yu; Kegong Tian; Shaobin Shang; Jianzhong Zhu
Journal:  Vet Res       Date:  2021-05-27       Impact factor: 3.683

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.